NASDAQ · PRQR
ProQR Therapeutics N.V financials
$1.650.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.7M | $19.7M | $7.2M | $3.9M | $1.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $18.7M | $19.7M | $7.2M | $3.9M | $1.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating income | -$51.5M | -$32.4M | -$38.5M | -$70.7M | -$58.3M | -$63.1M | -$66.6M | -$42.1M | -$42.0M | -$41.4M |
| Net income | -$49.5M | -$28.9M | -$31.1M | -$69.1M | -$60.7M | -$56.8M | -$63.7M | -$37.1M | -$43.7M | -$39.1M |
| Net margin | −265.2% | −146.9% | −431.7% | −1792.5% | −4549.8% | — | — | — | — | — |
| Diluted EPS | $-0.47 | $-0.33 | $-0.39 | $-0.97 | $-0.95 | $-1.13 | $-1.55 | $-1.08 | $-1.72 | $-1.67 |
| EBITDA | -$48.3M | -$29.5M | -$35.8M | -$68.0M | -$55.9M | -$63.1M | -$64.3M | -$41.1M | -$40.9M | -$40.2M |
| Operating cash flow | -$61.9M | -$37.9M | $23.8M | -$73.5M | -$26.0M | -$57.3M | -$49.3M | -$28.5M | -$35.0M | -$34.2M |
| Free cash flow | -$63.1M | -$42.1M | $19.7M | -$74.2M | -$26.5M | -$58.4M | -$50.0M | -$28.8M | -$35.1M | -$36.8M |
| Diluted shares | 105.3M | 86.1M | 81.0M | 71.6M | 64.2M | 50.1M | 41.0M | 34.1M | 25.4M | 23.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $108.4M | $155.5M | $131.5M | $94.8M | $213.2M | $92.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $5.7M | $4.8M | $4.7M | $6.8M | $50.1M | $21.1M |
| Total assets | $132.3M | $174.8M | $152.4M | $171.3M | $238.3M | $120.2M |
| Total liabilities | $74.4M | $82.6M | $106.7M | $104.6M | $109.6M | $51.4M |
| Shareholders' equity | $57.9M | $92.2M | $45.8M | $66.7M | $128.8M | $68.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology